中國先鋒醫藥(01345.HK)300萬美元攬韓國氧化鋯產品廠商25%股權
格隆匯1月20日丨中國先鋒醫藥(01345.HK)宣佈,公司通過子公司先鋒醫藥(香港)有限公司向一間韓國DMAX公司投資300萬美元。此次投資已於2019年12月獲得董事會一致表決通過。
根據雙方簽署的認購協議,DMAX公司向先鋒醫藥(香港)有限公司發行股份8,906股,代價為300萬美元。於此次發行完成後,公司將通過子公司持有DMAX公司25%的已發行股份,同時獲得委派一人作為DMAX公司董事的權利。
DMAX公司是韓國知名氧化鋯產品廠商,主要生產氧化鋯相關齒科產品,包括貼面、牙冠及種植體等。自2018年公司成為DMAX公司產品的中國大陸獨家代理商(以來,雙方一直共同致力於在中國推廣DMAX公司產品。DMAX公司的氧化鋯產品進入中國市場後,以其在醫學美容方面的獨特技術受到市場青睞。此次投資有助於雙方進一步深化合作,鞏固雙方夥伴關係,共同開拓DMAX公司產品在中國的市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.